Diamond Hill Capital Management Inc. Takes Position in The Cooper Companies, Inc. $COO

Diamond Hill Capital Management Inc. bought a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 567,243 shares of the medical device company’s stock, valued at approximately $38,890,000.

Other institutional investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after buying an additional 7,363 shares during the period. KLP Kapitalforvaltning AS boosted its position in shares of Cooper Companies by 1.9% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 69,500 shares of the medical device company’s stock valued at $4,946,000 after purchasing an additional 1,300 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Cooper Companies by 32.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 8,137 shares of the medical device company’s stock worth $579,000 after purchasing an additional 1,994 shares in the last quarter. Callan Family Office LLC lifted its stake in Cooper Companies by 12.7% during the second quarter. Callan Family Office LLC now owns 4,365 shares of the medical device company’s stock valued at $311,000 after purchasing an additional 493 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in Cooper Companies by 24.7% during the second quarter. Blue Trust Inc. now owns 1,362 shares of the medical device company’s stock valued at $97,000 after purchasing an additional 270 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Stock Up 2.5%

COO opened at $82.10 on Friday. The company has a market capitalization of $16.09 billion, a PE ratio of 43.67, a price-to-earnings-growth ratio of 2.34 and a beta of 1.03. The business has a 50-day moving average of $81.37 and a 200-day moving average of $74.53. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $95.43. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Insider Transactions at Cooper Companies

In other Cooper Companies news, insider Holly R. Sheffield bought 1,230 shares of the stock in a transaction on Tuesday, December 16th. The shares were purchased at an average cost of $80.75 per share, with a total value of $99,322.50. Following the completion of the transaction, the insider directly owned 39,052 shares of the company’s stock, valued at $3,153,449. This represents a 3.25% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cynthia L. Lucchese bought 1,784 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were bought at an average price of $84.06 per share, for a total transaction of $149,963.04. Following the completion of the acquisition, the director owned 9,445 shares of the company’s stock, valued at approximately $793,946.70. This represents a 23.29% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 16,014 shares of company stock valued at $1,304,416 in the last three months. 1.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

COO has been the topic of several research reports. Needham & Company LLC dropped their price target on Cooper Companies from $100.00 to $99.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Robert W. Baird boosted their target price on Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Citigroup reiterated a “neutral” rating and issued a $88.00 target price (up from $72.00) on shares of Cooper Companies in a report on Monday, December 8th. Stifel Nicolaus set a $95.00 target price on Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Finally, JPMorgan Chase & Co. lifted their price target on Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cooper Companies has an average rating of “Moderate Buy” and a consensus target price of $90.77.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.